How do pharmaceutical companies find good agency products?

For example, pharmaceutical commercial companies vigorously expand the original "general agent" business, which is a good development trend. Therefore, finding a good product to be the national general agent has become the top priority of all work. So how can we find a long-term variety with high profit, exclusive or patent protection and easy to win the bid? The author here provides some reference methods for everyone. First of all, the pharmaceutical companies located in this development direction can set up a special variety screening negotiation team, and the members can be part-time staff in the internal marketing department or other departments of the company. Its key tasks are: monitoring the drug approval and evaluation status of the National Drug Evaluation Center at any time; Regularly contact large domestic pharmaceutical R&D companies, research groups of medical colleges, China Academy of Sciences, Academy of Military Medical Sciences and other well-known medical research institutions to learn about the establishment of scientific research projects, declared varieties, transfer trends, intended buyers and other information. Doing this kind of work well can help the pharmaceutical general agent company to master the drug listing information in the next 3-5 years from the source, and also provide a lot of substitution opportunities for negotiating the national general agent, because the really good varieties have the agency negotiation or contract signing from the beginning of the project, and the variety agent with the document number can only act as the market supplement of the last general agent. It can be said that "the victory or defeat of the war was actually decided before the war." Secondly, we should actively contact the headquarters of well-known multinational pharmaceutical companies and their Asia-Pacific market business departments and other institutions, and actively negotiate the general agency rights of some leading drugs of these multinational companies in China, such as Shenzhen Jian 'an Medicine, Pioneer Medicine and Livzon Medicine. This model started and developed in China in the 1990s, and it is also very common internationally, such as Yongyu Medicine, Jebsen Foreign Firm and Livzon Medicine. Third, we should actively contact and negotiate with large domestic pharmaceutical companies. In recent years, many large pharmaceutical companies have submitted for approval or are applying for many varieties, and small and medium-sized pharmaceutical companies can sign general agency rights with them in advance. This kind of typical pharmaceutical companies are: Hengrui Pharmaceutical, Huabei Pharmaceutical and Wuhan Jianmin Pharmaceutical. Typical representatives of this agency model are: Shenzhen Ou Long Medicine, Jiangsu Kefeiping Medicine, etc. If this general agent product is a traditional Chinese medicine product, it is often very competitive, either a protected variety of traditional Chinese medicine or an exclusive variety, which has an advantage in bidding. It is such a model that "Beijing Yongzheng Medicine" always replaces "Xiaojin Capsule" and "Convenience Capsule" of "Wuhan Jianmin Medicine" for national distribution through attracting investment. Fourth, small and medium-sized pharmaceutical companies can also actively explore the second-line products of domestic joint ventures and wholly-owned multinational pharmaceutical companies. These products are often exclusive or patented in China and have unique advantages in pricing, bidding and even entering hospitals. These varieties are beyond the control of the self-built sales teams of these multinational pharmaceutical companies. Therefore, once these products have obtained the general agent right, they are generally long-term products. Because these products need long-term academic promotion, the general agent should be enough. In fact, the sales model of such products is almost equivalent to the practice of manufacturers building their own teams. Whether it is the establishment of sales team or the establishment and application of expert network, all a series of academic promotion work needs the general agent to complete. The typical representative of this model is Yangpu Fahrenheit Pharmaceutical Company. For small and medium-sized pharmaceutical commercial companies, they can expand the business of regional drug distributors by giving full play to their regional business advantages and make up for the decline in profits caused by not obtaining the post-bid distribution rights. To be a general agent in a certain area, you can also learn from the above methods on how to find good products. In addition to your capital, talents and distribution strength, you also need the top management of the general agent company to make efforts to establish contacts in the industry. Because of the complex interest relationship in the negotiation, if it is an unfamiliar customer relationship, the probability of success of the agency relationship is limited after all. Such regional general agent pharmaceutical companies include "Chengdu Wanlong Yikang Medicine".